Labs Have Published 110 Publications With Better Access to the Proteome
Our Chip Suite Reveals Cell Behavior & Proteome With Ease
Our Chip Families: Cellular & Proteomic Solutions
Take Virtual Tours of Our Products
Publications
See how top researchers are using our technology to predict durable responses and unlock pre-clinical meaning.
Areas of Interest
See how we can shift the paradigms in your programs
Updates
Enabling a New Era of Precision Medicine
Latest Customer Stories View Blog
Featured Events All Events
Trusted Worldwide
We innovated the only way to measure the true function of each cell and identify the rare subsets of superpowered cells driving response.
As a cancer research center with a key focus on CAR-T and other cell therapies, we feel that IsoPlexis will enable us to better characterize response and potentially predict whether cancer patients will respond to CAR-T therapy before treatment.
Christine Brown, PHD
City of Hope
The future is very powerful here. One can study autoimmunity and cancer biology, one can take out from the blood single cells, one can analyze those cells and get an overall picture from integrating that analysis.
Arnold Levine, PHD
Professor Emeritus, Simons Center for Systems Biology, Institute for Advanced Study
Quality assays are mainly descriptive with some objective parameters like cytokine production, cytotoxicity, and proliferation. Only recently, with PSI… can we start to differentiate products.
Marco L Davila, MD, PHD
Moffitt Cancer Center
We see potential in utilizing IsoPlexis’ single-cell system to help provide deeper resolution into the functional impacts of our therapeutics… This collaboration will enable us to apply the sensitivity of this solution to further our understanding of patient-specific responses to our immune therapies.
Jon Zalevsky, PHD
Chief Scientific Officer, Nektar Therapeutics
Through this research, we were able to highlight the important role a functionally versatile subpopulation of CAR-T cells may play in the fight against cancer. This could lead to new methods to optimize T-cell products.
Adrian Bot, MD, PHD
Vice President, Translation Sciences, Kite
Current assays that rely on a single-plex ELISA or even multiparametric flow cytometry don’t give you the level of resolution that the IsoPlexis platform can provide.
John Rossi
Director of Translational Sciences at Kite
“The best way to predict the future is to invent it.”
— Alan Kay
Spark the Next Breakthrough